LPV/r 100+25mg heat/st tabs/PAC-120
NOTE: The description below is for a standard product. It is notspecific to patent status and pricing policies that may apply at countrylevel. This information is available on request from Supply Division:Contact: [email protected]
General Description:
Lopinavir 100mg + Ritonavir 25mg film coated heat stable tablets, bottlepack of 120
Technical Specifications:
Each film coated tablet contains a fixed boosted protease inhibitorcombination of Lopinavir 100mg + Ritonavir 25mg in a heat stableformulation.
Therapeutic class:
Protease Inhibitors (PI)
Standard shelf life:
2 years (24 months)
Other available formulations:
The product may also be available in other formulations, pack sizes, orin combinations with other ARVs.
Guidelines for use:
For more details, please click the links listed below:
and
WHO EssentialMedicines Library
or your regional national guidelines
For details about paediatric dosage schemes, please click the linkslisted below:
WHO Generic tool for assessing paediatric ARV dosing
Indications:
Management of HIV-1 infection in infected adults and children above 2years of age in combination with at least two other antiretroviraldrugs. By mouth (PO)
NOTE
Ritonavir increases effect of Lopinavir; it is used in thisco-formulation as a booster to Lopinavir and this low dose incombination does not have intrinsic antiviral activity
Storage:
Do not store above 30°C (86°F)
Store in tightly closed original container
Keep out of reach and sight of children.
Dispensing instructions:
Dispense in original container. Do not repack
Tablet should not be broken or crushed. Should be swallowed whole.
Regulatory status:
For latest updates, please click the links listed below:
List of WHOPrequalified Medicines
List of USFDA approved and tentatively approved items
Important information regarding supply for thisproduct
Please click on the link:
http://www.unicef.org/supply/index_81996.html